기업 프로필 · Healthcare

Qiagen NV

QGEN · 미국
거래소
미국
국가 / 지역
USA
상장일
1996년 6월 28일
직원 수
5,500
웹사이트
www.qiagen.com
현재가
$42.04
실시간 · 2026년 7월 15일
적정 매수가
≤ $32
안전마진 진입가
베일리 성장 점수
42/100
다소 약함
내재가치 · 3단계 구간 현재가 $42.04 실시간 · 적정 내재가치 구간 내

종합 밸류에이션 구간 · 보수적 $30–$32 / 적정 $39–$53 / 낙관적 $58–$64. $42.04 기준, 적정 내재가치 구간 내.

보고서 발행 시 $41.51(2026년 7월 17일)

시가총액US$74.62억
매출 (TTM)US$20.99억
EBITDAUS$7.28억
순이익률19.16%
ROE11.93%
PER (TTM)18.46
선행 PER11.38
PEG0.91
EPSUS$1.96
배당수익률0%
52주 범위US$32.53 – US$57.82
애널리스트 목표주가US$43.82
애널리스트 평가3.9 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.